New hope for kids with recurring kidney disease

This study tested whether rituximab, an antibody treatment, works better than tacrolimus, a standard medication, to reduce relapses in children with a challenging form of kidney disease called steroid-sensitive nephrotic syndrome. Ninety-one children received one of the two treatments along with personalized nursing care and were followed for six months. Researchers measured how well the treatments worked, their side effects, and their impact on the children's quality of life.